Management of type 2 diabetes : the GLP-1 pathway

Abd A. Tahrani; Milan K. Piya; Anthony H. Barnett

doi:10.1002/fps.39

Management of type 2 diabetes : the GLP-1 pathway

Abd A. Tahrani, Milan K. Piya, Anthony H. Barnett

Western Sydney University

Research output: Contribution to journal › Article

Abstract

Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.

Original language	English
Pages (from-to)	18-28
Number of pages	11
Journal	Future Prescriber
Volume	9
Issue number	3
DOIs	https://doi.org/10.1002/fps.39
Publication status	Published - 2008

Keywords

diabetes
medical care
non-insulin-dependent diabetes
glucose
metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/fps.39

Cite this

@article{a60e2432a56f418b90b476c149364372,

title = "Management of type 2 diabetes : the GLP-1 pathway",

abstract = "Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.",

keywords = "diabetes, medical care, non-insulin-dependent diabetes, glucose, metabolism",

author = "Tahrani, {Abd A.} and Piya, {Milan K.} and Barnett, {Anthony H.}",

year = "2008",

doi = "10.1002/fps.39",

language = "English",

volume = "9",

pages = "18--28",

journal = "Future Prescriber",

issn = "1468-9871",

publisher = "Wiley & Sons",

number = "3",

}

TY - JOUR

T1 - Management of type 2 diabetes : the GLP-1 pathway

AU - Tahrani, Abd A.

AU - Piya, Milan K.

AU - Barnett, Anthony H.

PY - 2008

Y1 - 2008

N2 - Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.

AB - Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.

KW - diabetes

KW - medical care

KW - non-insulin-dependent diabetes

KW - glucose

KW - metabolism

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:43178

U2 - 10.1002/fps.39

DO - 10.1002/fps.39

M3 - Article

SN - 1468-9871

VL - 9

SP - 18

EP - 28

JO - Future Prescriber

JF - Future Prescriber

IS - 3

ER -

Management of type 2 diabetes : the GLP-1 pathway

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this